Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

NCT04617925 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT04617925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04617925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 2
Overall status
Completed
Start date
February 26, 2021
Completion date
July 17, 2025
Enrollment
35 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis